Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab combination in HER2-positive advanced breast cancer
NCT04759248Phase 2Active, not recruiting
- Sponsor
- SOLTI
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in HER2-positive breast cancer, sponsored by SOLTI. Started Mar 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04759248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759248.